Author(s): Isha Shah, Nensi Raytthatha, Jigar Vyas, Umesh Upadhyay

Email(s): ishashah3498@gmail.com

DOI: 10.52711/0975-4377.2021.00039   

Address: Isha Shah, Nensi Raytthatha, Dr. Jigar Vyas, Dr Umesh Upadhyay
Sigma Institute of Pharmacy, Ajwa-Nimeta Road, Waghodia, Baroda, Gujarat, 390019 India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 3,     Year - 2021


ABSTRACT:
There is a new world health crisis threatening the public with spread of COVID-19 (Coronavirus Disease-2019). The virus outbreak has been declared a public health emergency of international concern by World Health Organization (WHO). The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. We here summarize the current clinical characteristics data to guide potential COVID-19 about Prevention, Diagnosis, Treatments and Prevention of COVID-19. In this review, we extracted data from various Research Report, WHO guidelines and other articles. It is important to aware the readers that new data updating nearly every hour regarding clinical characteristics, diagnosis, treatment strategies, and outcomes COVID-19. All over the world the disease has caused varying degrees of illness. Patient shows various symptoms usually fever, cough, sore throat, breathlessness, fatigue, and malaise among others. The disease is being rehabilitate through general treatment, symptomatic treatment, by using antiviral drugs, oxygen therapy and by the immune system. It is necessary to recognize the potential cases as soon as possible and isolate the suspected people from the confirmed cases of COVID-19, to avert the potential transmission of infection to other patients and health care staff.


Cite this article:
Isha Shah, Nensi Raytthatha, Jigar Vyas, Umesh Upadhyay. A Systematic Review on COVID 19 Treatment and Management. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(3):230-8. doi: 10.52711/0975-4377.2021.00039

Cite(Electronic):
Isha Shah, Nensi Raytthatha, Jigar Vyas, Umesh Upadhyay. A Systematic Review on COVID 19 Treatment and Management. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(3):230-8. doi: 10.52711/0975-4377.2021.00039   Available on: https://rjpdft.com/AbstractView.aspx?PID=2021-13-3-10


REFERENCES:
1.    Merriam-Webster, Definition of Coronavirus by Merriam-Webster, Archived from the original on 2020.
2.    ICTV Taxonomy history: Orthocoronavirinae, International Committee on Taxonomy of Viruses (ICTV).
3.    WHO Q and A on coronaviruses (COVID-19) March 2020, A review. Available from: URL: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses.
4.    Shereen M.A, Khan S, COVID-19 infection: origin, transmission, and characteristics of human coronaviruses, Journal of Advanced Research, 2020.
5.    Gray R, Covid-19: How long does the coronavirus last on surfaces? A review. Available from: URL: https://www.bbc.com/ future/ article/20200317-covid-19-how-long-does-the-coronaviruslast-on-surfaces.
6.    Alaska department of Health and Social services, Human Coronaviruses, A review. Available from: URL: http://dhss.alaska.gov/dph/Epi/id/Pages/ Human-Coronavirus.aspx
7.    Murphy A, and Bell D.J, et al. COVID-19, Radiopedia review. Available from: URL: https:// radiopaedia.org/articles/covid-19-2?lang=us.
8.    Goldsmith CS, Comer JA, Lee WW, et.al. Ultrastructural characterization of SARS coronavirus, Emerging Infectious Diseases, 10 (2): 320–26.
9.    Lalchhandama, K. the chronicles of coronaviruses: the electron microscope, the doughnut, and the spike, Science Vision.20 (2):78–92.
10.    Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus assembly and morphology, Journal of Structural Biology, 174 (1):11–22.
11.    Lai MM, Cavanagh D, The molecular biology of coronaviruses, Advances in Virus Research. 48: 1–100.
12.    Cavanagh D, Mawditt K, Sharma M, Drury SE, Ainsworth HL, et al. Detection of a coronavirus from turkey poults in Europe genetically related to infectious bronchitis virus of chickens, Avian Pathology, Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser. 30 (4): 355–68.
13.    Naskalska, Antonina; Dabrowska, Agnieszka, Szczepanski, Artur, Membrane Protein of Human Coronavirus NL63 Is Responsible for Interaction with the Adhesion Receptor, Journal of Virology, 93(19).
14.    Neuman, Benjamin W.; Kiss, Gabriella; Kunding, Andreas H, et al. A structural analysis of M protein in coronavirus assembly and morphology, Journal of Structural Biology. 174 (1): 11–22.
15.    Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of medicinal chemistry.2006; 49(9):2845-2849.
16.    Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir Res. 2020:104786.
17.    Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020; 95:183–191.
18.    Liu X, Wang X-J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Gene Genome. 2020; 47(2):119–121.A review. Available from: URL: https:// doi.org/10.1016/j.jgg.2020.02.001.
19.    Lim J, Jeon S, and Shin H-Y, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RTPCR. J Kor Med Sci. 2020; 35.
20.    Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020; 81(1).
21.    Zhua Z, Luc Z, Xud T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020.A review. Available from: URL: https://doi.org/10.1016/j.jinf.2020.03.060.
22.    Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a Possible Therapeutic Option for the COVID-19. Travel Medicine and Infectious Disease. 2020.
23.    Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J Biol Chem. 2020:013056A review. Available from: URL: https://doi.org/10.1074/jbc. AC120.013056 In press.
24.    Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382(10):929–936.A review. Available from: URL: https://doi.org/10.1056/ NEJMoa2001191.
25.    Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265–269.
26.    Aukrust P, Barratt-Due A, Kasine T, et al. The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients. 2020.
27.    Ader F. Trial of Treatments for COVID-19 in Hospitalized Adults (Discovery). 2020.
28.    Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacol Ther. 2020; 107512.
29.    Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B. 2017; 93:449–463.
30.    Xuejiao L, Yingxia L, Clinical Study for Safety and Efficacy of Favipiravir in the Treatment of Novel Coronavirus Pneumonia (COVID-19). 2020; 2020.
31.    Cai Q, Yang M, Liu D, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. 2020. A review. Available from: URL: https://doi.org/10.1016/j.eng.2020. 03.007 In press.
32.    Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, MedRxiv, 2020.
33.    ISR ISfR. Tata Laksana Pasien Covid-19. 2020; 2020.
34.    Zhou F ea. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study.
35.    Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS medicine. 2006; 3(9): e343.
36.    Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129(6):1441-1452.
37.    Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2004; 31(4):304-309.
38.    Auyeung TW, Lee JS, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. The Journal of infection. 2005; 51(2):98- 102.
39.    Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. American journal of respiratory and critical care medicine. 2018; 197(6):757-767.
40.    https://www.financialexpress.com/lifestyle/health/ayurveda-medicines-for-covid-19-treatment-check-doses-timings/2099869/,access on 9 Jan 2020
41.    file:///C:/Users/User/Downloads/273-735-1-SM.pdf
42.    Agnihotri S, Kant S, Verma V, SM-IJ of, 2016 undefined. Role of Jalaneti and Pranayama in allergic rhinitis with asthma. ijoyppp.org.
43.    Meera S, Vandana Rani M, Sreedhar C, Robin DT. A review on the therapeutic effects of Neti Kriya with special reference to Jala Neti. J Ayurveda Integr Med. 2019 Jan.
44.    Sienkiewicz M, Łysakowska M, Pastuszka M, Bienias W, Kowalczyk E. The Potential of Use Basil and Rosemary Essential Oils as Effective Antibacterial Agents, Molecules. 2013 Aug; 18(8):9334–51.
45.    Eda N, Lee E, Shimizu K, Suzuki S, Tanabe Y, Akama T. Effects of yoga exercise on salivary beta-defensin 2. Springer. 2013 Oct;113(10):2621–7
46.    Longo V, metabolism MM-C, 2014 undefined. Fasting: molecular mechanisms and clinical applications. Elsevier.
47.    Patel S, Malhotra A, Gao X, Hu F, Sleep MN-, 2012 undefined. A prospective study of sleep duration and pneumonia risk in women.
48.    Gleeson M, Bishop N, Lindley MR, Mastana S. The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease the role of muscle mass and body temperature in the inflammatory response to upper-body exercise and heat View project Concurrent exercise
49.    Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. A pilot, open labeled, randomized controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep. 2019 Dec; 9(1):1–11.
50.    Sujan M, Rao M, RK-of neurosciences in, 2016 undefined. Influence of hydrotherapy on clinical and cardiac autonomic function in migraine patients.
51.    Verma A, Singhal A, Singh D, Vighyan Kendra K. Local health wisdom of rural women using medicinal plants. Vol. 9, Indian Journal of Traditional Knowledge. 2010.
52.    Prasad S, and BA-HMB, 2011 undefined. Turmeric, the golden spice.
53.    Chang Y, Labban J, Gapin J, research JE-B, 2012 undefined. The effects of acute exercise on cognitive performance: a meta-analysis. Elsevier.
54.    Organization WH. Cough and cold remedies for the treatment of acute respiratory infections in young children. 2001.

Recomonded Articles:

Author(s): Yamunappa, Ravi Kumar, Pooja Shetty, Prathibha Suvarna, Narayana Swamy VB

DOI: 10.5958/0975-4377.2016.00012.4         Access: Open Access Read More

Author(s): Swati Talokar, Rohan R Vakhariya, A.R Dhole

DOI: 10.5958/0975-4377.2017.00005.2         Access: Open Access Read More

Author(s): P. Lekshmi, K. Pramod, K.C. Ajithkumar

DOI: 10.5958/0975-4377.2016.00007.0         Access: Open Access Read More

Author(s): Sushant R. Jagtap, D.G Phadtare, R.B. Saudagar

DOI: 10.5958/0975-4377.2016.00021.5         Access: Open Access Read More

Author(s): Sayad Basha.K, Sheema Nafees. S, Nethravani. G, Thirumalesh Naik S.B

DOI: 10.5958/0975-4377.2016.00015.X         Access: Open Access Read More

Author(s): Ch. Anupama, P. Padmakumari, K. Abbulu, Arti Mohan, A. Ppratyusha

DOI:         Access: Open Access Read More

Author(s): B. Soujanya, G. Pavani Priya, T.E.G.K. Murthy

DOI: 10.5958/0975-4377.2015.00022.1         Access: Open Access Read More

Author(s): Debjit Bhowmik, Rishab Bhanot, K.P. Sampath Kumar

DOI: 10.5958/0975-4377.2018.00035.6         Access: Open Access Read More

Author(s): PS Gangane, KG Mahajan, HS Sawarkar, RR Thenge, VS Adhao

DOI:         Access: Open Access Read More

Author(s): Aparna Raut, PB Suruse, JG Awari, AK Raut, VV Kale

DOI:         Access: Open Access Read More

Author(s): Y. Raja Jayarao, D. Deborah, T. Ambedkar, S. Manohar Babu

DOI:         Access: Open Access Read More

Author(s): Swapnali A. Mohite, R. R. Vakhariya, S. K. Mohite, C. S. Magdum

DOI: 10.5958/0975-4377.2019.00017.X         Access: Open Access Read More

Author(s): Sethi RK, Sahoo SK, Das PK, Barik BB

DOI:         Access: Open Access Read More

Author(s): Ravi Kumar, Swati Patil, M. B. Patil, Sachin R. Patil, Mahesh S. Paschapur

DOI:         Access: Open Access Read More

Author(s): Raj Kumar Poddar, Pankaj Rakha, SK Singh, DN Mishra

DOI:         Access: Open Access Read More

Author(s): K. Vyshnavi, Madhuri Bhashetty, Namitha Swain, M. Venkataswamy, Alluri Ramesh

DOI: 10.5958/0975-4377.2017.00009.X         Access: Open Access Read More

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/0975-4377 


Recent Articles




Tags